Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Turkcapar, 2006, The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease, Rheumatol Int, 26, 663, 10.1007/s00296-005-0044-9
Salvarani, 2001, Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients, Scand J Gastroenterol, 36, 1307, 10.1080/003655201317097173
Salvarani, 2009, Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease, World J Gastroenterol, 15, 2449, 10.3748/wjg.15.2449
Atzeni, 2014, Rheumatic manifestations in inflammatory bowel disease, Autoimmun Rev, 13, 20, 10.1016/j.autrev.2013.06.006
Peluso, 2013, Enteropathic spondyloarthritis: from diagnosis to treatment, Clin Dev Immunol, 2013, 631408, 10.1155/2013/631408
Dougados, 1991, The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy, Arthritis Rheum, 34, 1218, 10.1002/art.1780341003
Scarpa, 1992, The arthritis of ulcerative colitis: clinical and genetic aspects, J Rheumatol, 19, 373
de Vlam, 2000, Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association, J Rheumatol, 27, 2860
Wordsworth, 2000, Arthritis and inflammatory bowel disease, Curr Rheumatol Rep, 2, 87, 10.1007/s11926-000-0045-3
Palm, 2002, Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study), J Rheumatol, 29, 511
Steer, 2003, Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease, J Rheumatol, 30, 518
Van Assche, 2013, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations, J Crohns Colitis, 7, 1, 10.1016/j.crohns.2012.09.005
Rodriguez-Reyna, 2009, Rheumatic manifestations of inflammatory bowel disease, World J Gastroenterol, 15, 5517, 10.3748/wjg.15.5517
Palm, 2001, The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study), Rheumatology (Oxford), 40, 1256, 10.1093/rheumatology/40.11.1256
Orchard, 1998, Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history, Gut, 42, 387, 10.1136/gut.42.3.387
Yuksel, 2011, Peripheral arthritis in the course of inflammatory bowel diseases, Dig Dis Sci, 56, 183, 10.1007/s10620-010-1260-z
Smale, 2001, Inflammatory bowel disease and spondylarthropathy, Arthritis Rheum, 44, 2728, 10.1002/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8
Veloso, 1996, Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients, J Clin Gastroenterol, 23, 29, 10.1097/00004836-199607000-00009
Manguso, 2004, Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis, Am J Gastroenterol, 99, 327, 10.1111/j.1572-0241.2004.04039.x
Manguso, 2005, Consecutive occurrence of rhinoconjunctivitis, seronegative spondyloarthritis and pyoderma gangrenosum in a patient with ulcerative colitis, Int J Colorectal Dis, 20, 79, 10.1007/s00384-004-0626-0
Rispo, 2005, Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease, Scand J Rheumatol, 34, 387, 10.1080/03009740510026698
Vavricka, 2011, Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort, Am J Gastroenterol, 106, 110, 10.1038/ajg.2010.343
Queiro, 2000, Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study, Clin Rheumatol, 19, 445, 10.1007/s100670070003
Braun, 1998, Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors, Arthritis Rheum, 41, 58, 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G
Khan, 2002, Update on spondyloarthropathies, Ann Intern Med, 136, 896, 10.7326/0003-4819-136-12-200206180-00011
Rudwaleit, 2009, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis, 68, 777, 10.1136/ard.2009.108233
Rudwaleit, 2011, The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Ann Rheum Dis, 70, 25, 10.1136/ard.2010.133645
Rothfuss, 2006, Extraintestinal manifestations and complications in inflammatory bowel diseases, World J Gastroenterol, 12, 4819, 10.3748/wjg.v12.i30.4819
Gravallese, 1988, Arthritic manifestations of inflammatory bowel disease, Am J Gastroenterol, 83, 703
De Vos, 2004, Review article: joint involvement in inflammatory bowel disease, Aliment Pharmacol Ther, 20, 36, 10.1111/j.1365-2036.2004.02044.x
Mielants, 1990, Destructive lesions of small joints in seronegative spondylarthropathies: relation to gut inflammation, Clin Exp Rheumatol, 8, 23
Mallas, 1976, Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27), Gut, 17, 906, 10.1136/gut.17.11.906
Oostveen, 1999, Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study, J Rheumatol, 26, 1953
Mera-Varela, 2013, Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study, PLoS One, 8, e58616, 10.1371/journal.pone.0058616
Laass, 2014, Diagnosis and classification of Crohn's disease, Autoimmun Rev, 13, 467, 10.1016/j.autrev.2014.01.029
Van Assche, 2010, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, J Crohns Colitis, 4, 7, 10.1016/j.crohns.2009.12.003
Conrad, 2014, Diagnosis and classification of ulcerative colitis, Autoimmun Rev, 13, 463, 10.1016/j.autrev.2014.01.028
Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis, J Crohns Colitis, 6, 965, 10.1016/j.crohns.2012.09.003
Cassinotti, 2014, Immunity, autoimmunity and inflammatory bowel disease, Autoimmun Rev, 13, 1, 10.1016/j.autrev.2013.06.007
Monteleone, 2014, Targets for new immunomodulation strategies in inflammatory bowel disease, Autoimmun Rev, 13, 11, 10.1016/j.autrev.2013.06.003
Geremia, 2014, Innate and adaptive immunity in inflammatory bowel disease, Autoimmun Rev, 13, 3, 10.1016/j.autrev.2013.06.004
Dignass, 2010, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management, J Crohns Colitis, 4, 28, 10.1016/j.crohns.2009.12.002
Orlando, 2011, The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease, Dig Liver Dis, 43, 1, 10.1016/j.dld.2010.07.010
Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management, J Crohns Colitis, 6, 991, 10.1016/j.crohns.2012.09.002
Braun, 2011, 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Ann Rheum Dis, 70, 896, 10.1136/ard.2011.151027
van der Heijde, 2011, 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis, Ann Rheum Dis, 70, 905, 10.1136/ard.2011.151563
Gossec, 2012, European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Ann Rheum Dis, 71, 4, 10.1136/annrheumdis-2011-200350
Ritchlin, 2009, Treatment recommendations for psoriatic arthritis, Ann Rheum Dis, 68, 1387, 10.1136/ard.2008.094946
Harrell, 2004, Mesalamine derivatives in the treatment of Crohn's disease, Gastroenterol Clin North Am, 33, 303, 10.1016/j.gtc.2004.02.010
Sandborn, 2001, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 121, 1088, 10.1053/gast.2001.28674
Haraoui, 2009, Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action, Semin Arthritis Rheum, 39, 176, 10.1016/j.semarthrit.2008.06.004
Ben-Horin, 2014, Optimizing anti-TNF treatments in inflammatory bowel disease, Autoimmun Rev, 13, 24, 10.1016/j.autrev.2013.06.002
Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492
Javaid, 2001, Comparison of calcaneal ultrasound and DXA to assess the risk of corticosteroid-induced osteoporosis: a cross-sectional study, Osteoporos Int, 12, 788, 10.1007/s001980170056
Grossman, 2010, American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Care Res (Hoboken), 62, 1515, 10.1002/acr.20295
De Cruz, 2012, Adalimumab prevents post-operative Crohn’s disease recurrence, and is superior to thiopurines: early results from the POCER study [abstract], Gastroenterology, 142, S212, 10.1016/S0016-5085(12)60794-X
Regueiro, 2009, Infliximab prevents Crohn's disease recurrence after ileal resection, Gastroenterology, 136, 10.1053/j.gastro.2008.10.051
Colombel, 2009, Adalimumab for the treatment of fistulas in patients with Crohn's disease, Gut, 58, 940, 10.1136/gut.2008.159251
Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn's disease, N Engl J Med, 350, 876, 10.1056/NEJMoa030815
Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804
Marshall, 2010, Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD004115
Gionchetti, 1998, Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis, Dis Colon Rectum, 41, 93, 10.1007/BF02236902
Sutherland, 2006, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 2, CD000544
Marshall, 1995, Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis, Aliment Pharmacol Ther, 9, 293, 10.1111/j.1365-2036.1995.tb00384.x
Velayos, 2006, Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study, Gastroenterology, 130, 1941, 10.1053/j.gastro.2006.03.028
Monterubbianesi, 2014, Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy, J Crohns Colitis, 10.1016/j.crohns.2014.01.006
Sandborn, 2006, Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study, Clin Gastroenterol Hepatol, 4, 203, 10.1016/j.cgh.2005.12.002
El Miedany, 2006, The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases, Am J Gastroenterol, 101, 311, 10.1111/j.1572-0241.2006.00384.x
Louis, 2012, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, 142, 10.1053/j.gastro.2011.09.034
Truelove, 1962, Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis, Br Med J, 2, 1708, 10.1136/bmj.2.5321.1708